Indefinite Delivery Contract 75N93023D00018

The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) awarded a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract to Resourcepath, LLC, a certified Woman-Owned Small Business, to provide a comprehensive array of diagnostic pre-clinical services. The $12 million DIAGNOSTICS PRE-CLINICAL SERVICES PROGRAM IDIQ contract has a 7-year ordering period through June 2030. Under this contract, Resourcepath was issued a $3,500 firm fixed price delivery order to perform pre-clinical diagnostic services program support in Sterling, Virginia. The contract scope includes providing services such as product development processes and documentation, recombinant proteins and monoclonal antibodies, biochemical reagents, clinical specimens and bacterial isolates, next-generation sequencing, immunoassays, nucleic acid amplification assays, and pre-pilot and pilot-scale GMP manufacturing. These services are intended to help a variety of investigators, including academics and companies, to develop in vitro diagnostic products for the detection, identification, and characterization of human infectious agents in support of NIAID's research priorities.

The original NIAID solicitation was a small business sources sought notice seeking capability statements from qualified small businesses to potentially fulfill technical requirements across multiple task areas. The agency anticipated awarding multiple IDIQ contracts to provide IVD product development support services, with the intent of enabling product developers to access a discrete subset of services to propel new diagnostic products toward regulatory clearance. No set-aside was designated for the forthcoming solicitation.